JPRN-UMIN000009159招募中未知
Randomised clinical trial of interferon rebound therapy for chronic hepatitisB patients - Interferon rebound therapy for chronic hepatitisB patients
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Cirrhosis or hepatic failure such as chronic liver diseases, e.g. autoimmune hepatitis and alcoholic hepatitis (2)History of pneumonitis (3) Severe other diseases (4)Severe mental disorders (5)Pregnant woman or woman who has possibility of pregnancy or woman while suckling (6)Doctor judged patient as inappropriate person in this trial
研究者
相似试验
已完成
2 期
Open trial of the interferon therapy for withdrawal of entecavir for patient with chronic hepatitis Bchronic hepatitis BJPRN-UMIN000004906Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences15
进行中（未招募）
1 期
The purpose of this study is to evaluate how effective, safe and tolerable Sofosbuvir (SOF)/Velpatasvir(VEL) is when taken by people with recent hepatitis C virus (HCV) infection, in particular whether the length of treatment can be shortened. Study participants will be randomly (occur by chance) assigned into one of the two different groups. The short treatment duration group will receive SOF/VEL for 6 weeks and the standard treatment duration group will receive SOF/VEL for 12 weeks.Recent hepatitis C virus infection all genotypes.MedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004243-39-NLniversity of New South Wales Australia250
进行中（未招募）
1 期
A study to evaluate how effective, safe and tolerable Sofosbuvir/Velpatasvir is when taken by people with recent hepatitis C virus infection, in particular whether the length of treatment can be shortened.Recent hepatitis C virus infection all genotypes.MedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004243-39-GBThe University of New South Wales Australia250
招募中
不适用
Randomized trial of new oral anti hepatitis B drug (entecavir) plus interferon versus another oral anti hepatitis B drug (lamivudine) plus interferon in chronic hepatitis B in children.CTRI/2016/04/006820jjal Poddar
招募中
3 期
Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patientschronic hepatitis type CJPRN-UMIN000005598Kyoto University Graduate School of Medicine Center for Genomic Medicine100